BMY241011C56000
- 0.01
- 0.000.00%
Bristol-Myers Squibb Newsroom
Bristol Myers Squibb (BMY) Stock Falls Amid Market Uptick: What Investors Need to Know
Cancer-Focused Perspective Therapeutics Stock Trades Lower After Drug Study Report
Perspective Falls After Data for Radiopharmaceutical in Skin Cancer
Morgan Stanley Maintains Bristol-Myers Squibb(BMY.US) With Sell Rating, Maintains Target Price $37
Kyverna, Cabaletta Started at Buys by UBS on CAR T Therapy Potential
Today's Analyst Rating | Alibaba Price Target Raised to $115 by Morgan Stanley, TD Cowen Downgrades PepsiCo to Hold
Correction to Old Drug Repurposed Article on Oct. 7 -- WSJ
BMY Buoyed by Recent Regulatory Updates: How to Play the Stock?
UBS Maintains Bristol-Myers Squibb(BMY.US) With Hold Rating, Raises Target Price to $54
TD Cowen Maintains Bristol-Myers Squibb(BMY.US) With Hold Rating, Raises Target Price to $59
Express News | Barclays Maintains Underweight on Bristol-Myers Squibb, Raises Price Target to $43
Reviva Pharmaceuticals Schizophrenia Drug Demonstrates Strong Efficacy On Heels Of Bristol Myers, FDA Approval: Analyst
Unveiling 11 Analyst Insights On Bristol-Myers Squibb
Bristol-Myers Squibb Is Maintained at Hold by TD Cowen
Bristol-Myers Squibb Analyst Ratings
10 Health Care Stocks Whale Activity In Today's Session
Top 10 Rated U.S. Value Stocks per SA Quant Metrics
Pfizer Stock Rises After It Gets an Activist. What Starboard's Track Record With Pharma Tells Us.
S&P 500 Could Reach 6,300 In 12 Months, Says Goldman Sachs, Driven by 'Strong AI Demand' And 'Margin Expansion'
Pfizer Stock Slump: Will Starboard's Billion-Dollar Bet Spark Rebound?